Home›Compare›MangoRx vs Syra Rx

MangoRx vs Syra Rx: Which Is Better?

Head-to-head comparison of MangoRx and Syra Rx based on our independent scoring across trust, value, experience, product range, and reputation — plus real pricing for the treatments they both offer.

Our Verdict

MangoRx scores higher overall in our independent evaluation (58/100 vs 53.5/100), leading on trust & safety, value, experience, reputation. Syra Rx comes out ahead on product range. Syra Rx has the lower entry price (from $30/mo vs $50/mo), so the better value depends on which treatment you need.

58

MangoRx is the Dallas-based men's health telehealth brand of Nasdaq-listed Mangoceuticals, selling compounded ED, hair-loss and oral semaglutide products alongside injectable and oral (Kyzatrex) testosterone.

Visit MangoRx
54
Syra Rx
Below Average

Syra Rx is a 2026-launched, affiliate-distributed telehealth storefront for compounded GLP-1s, NAD+, sermorelin, tesamorelin and ED treatment, with clinical care outsourced to LocumTele and fulfillment by Rush Pharmacy.

Visit Syra Rx

Score Breakdown

DimensionMangoRxSyra Rx
Overall Score58/100 ✓53.5/100
Trust & Safety30%55/100 ✓50/100
Value25%62/100 ✓56/100
Experience20%58/100 ✓50/100
Product Range15%66/10070/100 ✓
Reputation10%45/100 ✓40/100

At a Glance

Founded20212026
HeadquartersDallas, TX—
Publicly tradedYes (MGRX)No
Treatment categories53
Treatments listed55
Starting price$50/mo$30/mo

Pricing Where They Compete

Prices shown are based on our most recent research and may not reflect current pricing. Telehealth providers update their pricing frequently. Always verify pricing directly with the provider before purchasing.

CategoryMangoRxSyra Rx
Sexual Health$59–$75
Mango ED (sildenafil or tadalafil)
$30–$100
ED Treatment
Weight Loss / GLP-1$299
Slim (compounded oral semaglutide ODT)
$199–$399
Compounded GLP-1 (semaglutide/tirzepatide)

MangoRx

+Injectable TRT program priced at $99/month with doctor visits, lab work and medication included (per February 2026 company release and current site listing)
+Offers a branded FDA-approved oral testosterone option (Kyzatrex-based 'Prime') alongside compounded injectable TRT, which few small men's-health platforms carry
+Public-company SEC disclosures make ownership, pharmacy relationships and finances unusually visible for a brand this size
−Going-concern risk: $228,688 cash on hand at June 30, 2026 against a six-month net loss of $4.7M, per its Q2 2026 10-Q
−Compounded products are filled by Epiq Scripts, a pharmacy majority-owned (52%) by the CEO, a related-party arrangement
−Very small patient base: Q2 2026 revenue of $68,757, down 59% year over year, and only 18 Trustpilot reviews
Read the full MangoRx review →

Syra Rx

+Discloses its provider network (LocumTele) and dispensing pharmacy (Rush Pharmacy) by name in the FAQ
+One of few consumer brands offering tesamorelin alongside sermorelin and NAD+
+States a fast fulfillment window (usually 1–2 business days after approval)
−No prices published anywhere on the site; costs appear only inside third-party intake funnels
−Launched in 2026 with no independent patient reviews and no physical address disclosed
−Terms of service cover only GLP-1 services even though the site markets peptides, NAD+ and ED treatment
Read the full Syra Rx review →

MangoRx vs Syra Rx — FAQ

Is MangoRx better than Syra Rx?

▾

MangoRx scores higher overall in our independent evaluation (58/100 vs 53.5/100), leading on trust & safety, value, experience, reputation. Syra Rx comes out ahead on product range. Syra Rx has the lower entry price (from $30/mo vs $50/mo), so the better value depends on which treatment you need.

Is MangoRx or Syra Rx cheaper?

▾

Syra Rx has the lower starting price (from $30/mo vs $50/mo for MangoRx). Starting prices are for the cheapest treatment each offers — compare the specific treatment you need, and check what each price includes.

What do MangoRx and Syra Rx both offer?

▾

Both platforms treat Sexual Health, Weight Loss / GLP-1. MangoRx covers 5 treatment categories total and Syra Rx covers 3.

Still deciding?